Abstract
This study investigates the effects of mefepronic acid (MA), a PPAR-α agonist, on hepatic metabolic functions and reproduction of postpartum dairy cows. Sixty Friesian cows were divided into Group A (administered 5g of MA IM, within 24 hrs after calving, on the 3rd and 5th day postpartum) and Group B (control). All the cows were blood sampled within 24 hrs of calving (Day 0), on Day 3, 5, 10, 15, 30, and 40 postpartum. On plasma, metabolic and biochemical parameters were determined. Liver biopsies were performed on Day 0, 15 and 30 for the evaluation of hepatic lipid and glycogen content. Reproductive parameters were also evaluated.
In Group A, blood HDL, glucose and cholesterol increased till the end of the study, in accordance with the histological results. PPAR-α immunopositive cells increased in liver slices of Group A, too. Reproductive parameters improved in Group A. This study highlights the beneficial effects of mefepronic acid on the hepatic metabolism and reproductive parameters of post-partum dairy cows.
Keywords: Dairy cow, fatty acids, lipid, liver metabolism, mefepronic acid, reproduction.
Endocrine, Metabolic & Immune Disorders - Drug Targets
Title:Effects of Mefepronic Acid (2-Phenoxy-2-Methyl Propionic Acid) on Hepatic Metabolism and Reproductive Parameters in Postpartum Dairy Cows
Volume: 14 Issue: 2
Author(s): Annalisa Rizzo, Carlo Gazza, Maddalena Mutinati, Salvatore Desantis, Sara Zizza, Giovanni D'Onghia, Gianfranco D'Onghia, Marianna Pantaleo and Raffaele L. Sciorsci
Affiliation:
Keywords: Dairy cow, fatty acids, lipid, liver metabolism, mefepronic acid, reproduction.
Abstract: This study investigates the effects of mefepronic acid (MA), a PPAR-α agonist, on hepatic metabolic functions and reproduction of postpartum dairy cows. Sixty Friesian cows were divided into Group A (administered 5g of MA IM, within 24 hrs after calving, on the 3rd and 5th day postpartum) and Group B (control). All the cows were blood sampled within 24 hrs of calving (Day 0), on Day 3, 5, 10, 15, 30, and 40 postpartum. On plasma, metabolic and biochemical parameters were determined. Liver biopsies were performed on Day 0, 15 and 30 for the evaluation of hepatic lipid and glycogen content. Reproductive parameters were also evaluated.
In Group A, blood HDL, glucose and cholesterol increased till the end of the study, in accordance with the histological results. PPAR-α immunopositive cells increased in liver slices of Group A, too. Reproductive parameters improved in Group A. This study highlights the beneficial effects of mefepronic acid on the hepatic metabolism and reproductive parameters of post-partum dairy cows.
Export Options
About this article
Cite this article as:
Rizzo Annalisa, Gazza Carlo, Mutinati Maddalena, Desantis Salvatore, Zizza Sara, D'Onghia Giovanni, D'Onghia Gianfranco, Pantaleo Marianna and Sciorsci L. Raffaele, Effects of Mefepronic Acid (2-Phenoxy-2-Methyl Propionic Acid) on Hepatic Metabolism and Reproductive Parameters in Postpartum Dairy Cows, Endocrine, Metabolic & Immune Disorders - Drug Targets 2014; 14 (2) . https://dx.doi.org/10.2174/1871530314666140223184913
DOI https://dx.doi.org/10.2174/1871530314666140223184913 |
Print ISSN 1871-5303 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3873 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Recent Advances in Nanoneurology for Drug Delivery to the Brain
Current Nanoscience IL-17A and Multiple Sclerosis: Signaling Pathways, Producing Cells and Target Cells in the Central Nervous System
Current Drug Targets Allergen-Induced Inflammation
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry The Prospect of Stem Cells as Multi-Faceted Purveyors of Immune Modulation, Repair and Regeneration in Multiple Sclerosis
Current Stem Cell Research & Therapy From Leflunomide to Teriflunomide: Drug Development and Immunosuppressive Oral Drugs in the Treatment of Multiple Sclerosis
Current Neuropharmacology Current Proposed Mechanisms of Action of Intravenous Immunoglobulins in Inflammatory Neuropathies
Current Neuropharmacology A Review of Recent Patents on the ASICs as a Key Drug Target
Recent Patents on Biotechnology Endothelial Cells in Inflammation and Angiogenesis
Current Drug Targets - Inflammation & Allergy Editorial (Thematic Issue: GABAergic Modulation as Treatment Strategy: Consideration of Several Diseases)
Current Pharmaceutical Design The Long and Winding Road to Cancer Treatment: The Trail System
Current Pharmaceutical Design Circumventing Immune Tolerance Through Epigenetic Modification
Current Pharmaceutical Design Therapeutic Options for the Treatment of 2019-Novel Coronavirus in India: A Review
Coronaviruses Transient Focal Lesions in the Splenium of the Corpus Callosum with Restricted Diffusion: An Enigma
Current Medical Imaging Microglial dependent protective effects of neuroactive steroids
CNS & Neurological Disorders - Drug Targets Targeted Delivery of Montelukast for the Treatment of Alzheimer’s Disease
CNS & Neurological Disorders - Drug Targets The Blood-Central Nervous System Barriers Actively Control Immune Cell Entry into the Central Nervous System
Current Pharmaceutical Design Regulatory T Cells and Allergic Disease
Inflammation & Allergy - Drug Targets (Discontinued) Inflammation in Ischemic Stroke Subtypes
Current Pharmaceutical Design Glycolipid Stimulators for NKT Cells Bearing Invariant Vα19-Jα33 TCR α Chains
Mini-Reviews in Medicinal Chemistry Central Nervous System-Related
Current Bioactive Compounds